Neurotech InternationalNTILF 34 Buyback Yield % is -19.23 as of Jun. 28, 2026. GuruFocus rates NTILF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 743 Biotechnology companies, Neurotech International ranks worse than 65.41% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NTILF vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Neurotech International's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurotech International Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neurotech International's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Neurotech International's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurotech International (NTILF) has a Buyback Yield % of -19.23 as of Jun. 28, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neurotech International and its competitors. According to the industry distribution chart, Neurotech International ranks #486 out of 743 companies in the Biotechnology industry, placing it in the top 65.4%.
Is Neurotech International's Buyback Yield % too high?
Neurotech International's current Buyback Yield % is -19.23. Based on the distribution chart, Neurotech International ranks #486 out of 743 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Neurotech International has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Neurotech International's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neurotech International ranks #486 out of 743 companies for Buyback Yield %. This places Neurotech International in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neurotech International and its competitors. Neurotech International's current Buyback Yield % is -19.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurotech International stock overvalued right now?
Neurotech International (NTILF) has a current Buyback Yield % of -19.23. The current Buyback Yield % is -19.23. Neurotech International's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Neurotech International (NTILF), the current Buyback Yield % is -19.23 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
34GF Score
Get the complete analysis for NTILF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTILF has been successfully added to your 
